Exploring Breakthrough Biotech Stocks: $ENZC, $CYDY, $HGEN, $HALB
https://www.digitaljournal.com/pr/news/getnew...-hgen-halb
Exploring Breakthrough Biotech Stocks: ENZC, CYDY, HGEN, HALB
The biotech sector has generated a lot of interest among investors over the past few years and for good reason too, given the innovative work being accomplished by many companies. Here is a look at four biotech stocks that could be worth tracking.
Enzolytics Inc (OTC:ENZC) - The company is involved in drug development through the commercialization of its proprietary protein and monoclonal antibodies to treat infection-debilitating diseases. At this point, Enzolytics Inc is involved in working on several therapeutics to target multiple infectious diseases.
On July 11 the company announced that it had filed a Supplemental Information report for providing the details in connection with the non-binding letter of intent it had entered into with Sagaliam Acquisition Corp regarding the sales of Enzolytics’ two operating subsidiaries Virogenetics Inc and Biogenysis. The transaction would be worth $450 million.
The Chief Executive Officer of Sagaliam Barry Kostiner noted that the two companies were working together so that the Enzolytics shareholders could get the benefits of the eventual NASDAQ listing. It would protect the interests of the shareholders at a time of market volatility.
CytoDyn Inc (OTC:CYDY) - The company is currently involved in the development of and commercialization of the investigational humanized monoclonal antibody leronlimab. The company is engaged in studying the effect of leronlimab in a range of therapeutic areas, which includes cancer, autoimmune conditions, and infectious diseases. On May 24 the company announced that its President Dr. Cyrus Arman had decided to go on a medical leave of absence.
The Chief Financial Officer, Antonio Migliarse, took up the position of President on an interim basis. At the time it was announced by CytoDyn that Migliarese would be supported by Dr. Melissa Palmer, the Chief Medical Officer, and Dr. Salah Kivlighn, who had joined the company as a clinical and medical advisor not too long ago at the time. At the time, CytoDyn also announced that it was going to host a webcast for the investment community in the future.
Humanigen Inc (NASDAQ:HGEN) - The clinical-stage biopharmaceutical company is involved in the development of lenzilumab, which is a first-in-its-class antibody that neutralizing granulocyte-macrophage colony-stimulating factor. On June 9 the company made further announcements about the positive results that had been reported about lenzilumab.
The company noted that the additional data revealed that in the patients who had been treated with lenzilumab and azacitidine, the blood monocyte count went down as much as fivefold, there was a two-fold reduction in pro-monocytes and the percentage of blast cells and C-reactive proteins went down over threefold. The results were significant since they demonstrated that lenzilumab could help in the normalization of hematologic and inflammatory aberrations associated with CMML. Additionally, it could also help in improving the conditions of the participants involved.
Halberd Corporation (OTC:HALB) - In the past week the Halberd Corporation stock has been one of the notable movers as it delivered gains of 29% during the period. The company owns the global rights to three issued patents and has also filed 22 related PCT, provisional, or utility patent applications.
The application had been made by Halberd Corporation for boosting its value for shareholders and also become an attractive proposition for development partners. On May 31 Halberd Corporation announced that the impact and sample collection about Phase 1 of the preclinical model testing of its nasal spray had been completed by Mississippi State University. The spray is meant to address the effects of traumatic brain injuries.
The company also announced that Youngstown State University had been successful in eliminating further more strains of Candida auris from the samples that had been sent over by the Center for Disease Control. The university used the company's extracorporeal laser eradication methodology for the purpose. Earlier on the researchers at Youngstown State University had also been successful in eliminating E. coli through the use of as little as 10% of the laser power that had been necessary in the initial stages of eradication testing.
https://www.digitaljournal.com/pr/news/getnew...-hgen-halb
Exploring Breakthrough Biotech Stocks: ENZC, CYDY, HGEN, HALB
The biotech sector has generated a lot of interest among investors over the past few years and for good reason too, given the innovative work being accomplished by many companies. Here is a look at four biotech stocks that could be worth tracking.
Enzolytics Inc (OTC:ENZC) - The company is involved in drug development through the commercialization of its proprietary protein and monoclonal antibodies to treat infection-debilitating diseases. At this point, Enzolytics Inc is involved in working on several therapeutics to target multiple infectious diseases.
On July 11 the company announced that it had filed a Supplemental Information report for providing the details in connection with the non-binding letter of intent it had entered into with Sagaliam Acquisition Corp regarding the sales of Enzolytics’ two operating subsidiaries Virogenetics Inc and Biogenysis. The transaction would be worth $450 million.
The Chief Executive Officer of Sagaliam Barry Kostiner noted that the two companies were working together so that the Enzolytics shareholders could get the benefits of the eventual NASDAQ listing. It would protect the interests of the shareholders at a time of market volatility.
CytoDyn Inc (OTC:CYDY) - The company is currently involved in the development of and commercialization of the investigational humanized monoclonal antibody leronlimab. The company is engaged in studying the effect of leronlimab in a range of therapeutic areas, which includes cancer, autoimmune conditions, and infectious diseases. On May 24 the company announced that its President Dr. Cyrus Arman had decided to go on a medical leave of absence.
The Chief Financial Officer, Antonio Migliarse, took up the position of President on an interim basis. At the time it was announced by CytoDyn that Migliarese would be supported by Dr. Melissa Palmer, the Chief Medical Officer, and Dr. Salah Kivlighn, who had joined the company as a clinical and medical advisor not too long ago at the time. At the time, CytoDyn also announced that it was going to host a webcast for the investment community in the future.
Humanigen Inc (NASDAQ:HGEN) - The clinical-stage biopharmaceutical company is involved in the development of lenzilumab, which is a first-in-its-class antibody that neutralizing granulocyte-macrophage colony-stimulating factor. On June 9 the company made further announcements about the positive results that had been reported about lenzilumab.
The company noted that the additional data revealed that in the patients who had been treated with lenzilumab and azacitidine, the blood monocyte count went down as much as fivefold, there was a two-fold reduction in pro-monocytes and the percentage of blast cells and C-reactive proteins went down over threefold. The results were significant since they demonstrated that lenzilumab could help in the normalization of hematologic and inflammatory aberrations associated with CMML. Additionally, it could also help in improving the conditions of the participants involved.
Halberd Corporation (OTC:HALB) - In the past week the Halberd Corporation stock has been one of the notable movers as it delivered gains of 29% during the period. The company owns the global rights to three issued patents and has also filed 22 related PCT, provisional, or utility patent applications.
The application had been made by Halberd Corporation for boosting its value for shareholders and also become an attractive proposition for development partners. On May 31 Halberd Corporation announced that the impact and sample collection about Phase 1 of the preclinical model testing of its nasal spray had been completed by Mississippi State University. The spray is meant to address the effects of traumatic brain injuries.
The company also announced that Youngstown State University had been successful in eliminating further more strains of Candida auris from the samples that had been sent over by the Center for Disease Control. The university used the company's extracorporeal laser eradication methodology for the purpose. Earlier on the researchers at Youngstown State University had also been successful in eliminating E. coli through the use of as little as 10% of the laser power that had been necessary in the initial stages of eradication testing.
